Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 Instrument as a Clinical Decision Aid in the Routine Clinical Care of Patients With Systemic Sclerosis

Norina Zampatti; Alexandru Garaiman; Suzana Jordan; Rucsandra Dobrota; Mike Oliver Becker; Britta Maurer; Oliver Distler; Carina Mihai


Arthritis Res Ther. 2021;23(125) 

In This Article


In a large real-life cohort of unselected patients with SSc, we found a significant association of the UCLA GIT 2.0 score with the interpretation of GI symptoms by rheumatologists and consecutive recommendations for EGD. However, there was no association between the UCLA GIT 2.0 score, or its subscales, with endoscopic esophagitis, nor with any pathologic findings on EGD. Even the correlation between single symptoms, such as heartburn and dysphagia, and endoscopic esophagitis, was poor. We conclude that, while using the UCLA GIT 2.0 in the routine care of patients with SSc may help the rheumatologist to better understand the burden of GI symptoms in the individual patient, it should not be used as a stand-alone instrument to identify an indication of EGD. The question of whether all or selected patients with SSc should be investigated by EGD needs to be addressed by further studies.